ACS nanoJul 7, 2026

A Lung-Directed T Cell Nanovaccine Links Lung Immune Activation to Bodywide Anti-Cancer Response in Non-Small-Cell Lung Cancer

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Jul 8, 2026

Abstract

Lung-targeted lipid nanoparticles significantly prolonged survival in orthotopic models of Non-Small-Cell Lung Cancer (NSCLC).

Lung-enriched gamma delta T cells are identified as a critical component in NSCLC.
Analysis of patient data indicates that gamma delta T cell and CD1d signatures correlate with improved survival in NSCLC patients.
The engineered lipid nanoparticles preferentially accumulate in the lung after intravenous administration.
Activation of gamma delta T cells and enhanced CD8+ T cell infiltration were observed in NSCLC models treated with the nanovaccine.
Depletion of gamma delta T cells eliminated the therapeutic benefits, highlighting their role as essential effector cells.
Splenectomy reduced the effectiveness of the vaccine, indicating the importance of systemic immune interactions.

Simplified

Non-Small-Cell Lung Cancer (NSCLC) often responds poorly to immune checkpoint blockade due to its immunosuppressive, "cold" tumor microenvironment. Activating alternative immune effectors may overcome this limitation. Here we identified lung-enriched γδ T cells as a key compartment in NSCLC and developed a lung-targeted lipid nanovaccine to activate them in situ. Analysis of patient transcriptomic data sets reveals that γδ T cell and CD1d signatures are associated with improved patient survival in NSCLC. Using this insight, we engineered α-galactosylceramide (α-GalCer) and poly(I:C)-loaded lipid nanoparticles that preferentially accumulated in the lung after intravenous administration. In orthotopic NSCLC models, the nanovaccine activated γδ T cells, enhanced functional CD8⁺ T cell infiltration, remodeled the immunosuppressive tumor microenvironment, and significantly prolonged survival. Depletion of γδ T cells abolished therapeutic benefit, demonstrating that γδ T cells represented the important effector population for this strategy. Furthermore, splenectomy attenuated vaccine efficacy, suggesting a contribution of systemic immune crosstalk to vaccine efficacy. Together, these findings establish a γδ T cell-centered lung-targeted immunotherapy strategy for treating immune-resistant NSCLC.

Full Text

Full text is available at the source.

View Full Text ↗

A Lung-Directed T Cell Nanovaccine Links Lung Immune Activation to Bodywide Anti-Cancer Response in Non-Small-Cell Lung Cancer

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief